Equities

Gabelli Healthcare & WellnessRx Trust

GRX:NYQ

Gabelli Healthcare & WellnessRx Trust

Actions
FinancialsClosed End Investments
  • Price (USD)10.14
  • Today's Change0.04 / 0.40%
  • Shares traded17.34k
  • 1 Year change+16.42%
  • Beta1.0383
Data delayed at least 15 minutes, as of Nov 22 2024 21:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Gabelli Healthcare & WellnessRx Trust had relatively flat revenues (4.06m to 3.98m), though the company grew net income from a loss of 47.44m to a gain of 422.80k. A reduction in the cost of goods sold as a percentage of sales from 160.90% to 142.81% was a component in the net income growth despite flat revenues.
Gross margin-49.75%
Net profit margin-144.67%
Operating margin-60.64%
Return on assets-2.21%
Return on equity-2.92%
Return on investment-2.22%
More ▼

Balance sheet in USDView more

Gabelli Healthcare & WellnessRx Trust has a Debt to Total Capital ratio of 23.78%, a lower figure than the previous year's 31.88%.
Current ratio1.67
Quick ratio--
Total debt/total equity0.312
Total debt/total capital0.2378
More ▼

Growth rates in USD

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 100.95%. Additionally, five year annualized dividend per share growth is in-line with the industry average relative to its peers.
Div yield(5 year avg)5.83%
Div growth rate (5 year)2.90%
Payout ratio (TTM)--
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-246.43
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.